CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.
about
CRISPR/Cas9: Transcending the Reality of Genome Editing.Genome-Edited T Cell Therapies.mCAL: A New Approach for Versatile Multiplex Action of Cas9 Using One sgRNA and Loci Flanked by a Programmed Target Sequence.Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancerTargeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editingMethod for Dual Viral Vector Mediated CRISPR-Cas9 Gene Disruption in Primary Human Endothelial CellsAdvancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.CRISPR: express delivery to any DNA address.Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.Modeling of Autism Using Organoid Technology.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.Therapeutic gene editing: delivery and regulatory perspectivesThe CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups.Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells.Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemiaHuman CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework.The Future of CRISPR Applications in the Lab, the Clinic and Society.Human Pluripotent Stem Cells to Produce Cell-based Cancer Immunotherapy.PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?Application of Genome Editing Techniques in Immunology.A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.CAR-T cells: the long and winding road to solid tumors.Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells.[First use of CRISPR for gene therapy].Ligase IV inhibitor SCR7 enhances gene editing directed by CRISPR-Cas9 and ssODN in human cancer cells.Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy.In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.Translation of CRISPR Genome Surgery to the Bedside for Retinal Diseases.The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy.Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 with improved proof-reading enhances homology-directed repair.Immuno-Oncology: Emerging Targets and Combination TherapiesSelf-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma
P2860
Q33632925-0F628CBA-3246-4A8A-9073-FDADC3E135C6Q33729598-1A6BAFD8-4503-4E09-9CB0-974E7017FF6DQ36019453-44B939D0-CE73-47AA-BECC-9E6B555A8FA2Q36329068-C638E822-E37F-4D7F-A256-EFD08B9AFB31Q37293184-52E587F5-1C9D-4442-9E4D-1EA4AE275480Q37642712-EB26970D-67A1-49CD-9CA6-F6D231A87BC7Q38691942-20BBF047-295B-48C3-9116-9DD8975856A5Q38797121-E37B0A71-8FC5-4413-B66A-BD205A844362Q38836740-8B07963E-7476-4909-BAEA-24641945280EQ39008875-0A440ABE-293C-4513-984C-FCD81C490150Q39039017-F677461E-887F-4D8D-AAB7-F91E10F8727BQ39230418-CE59EB8D-CE31-43D5-AA01-E88156288D50Q39260698-1067F3F2-A7BF-43F9-A9A6-AE3CB4485A89Q39319380-0E808702-3CC8-4E65-83C5-1A3200D84ADDQ39418546-28D3DA84-1249-4D8E-8F39-2AB71C7C0807Q40336060-33CD04CF-232E-40A5-A188-1AE9D9D7854DQ41057575-75C28AB6-7C95-4B17-9BC1-2429305FF1DEQ41558781-14952D50-B1F0-4832-BF71-81F0D4752CDCQ41660817-451876E0-C4C9-4259-B447-8FC5F77F4EEAQ42576424-333485A0-AD91-4574-9CFF-D3F757C6BD83Q45872592-7798D12A-BD40-4F0F-A773-8E3C415F9DF8Q45874266-1C334214-5074-4CAB-932D-29DBF7A36161Q46262974-7B71175E-D62D-449E-B3E2-BAC64ED755AAQ46350666-A7DB8879-CF32-4692-B30D-13AEF5FE3142Q47137043-1987998A-8405-4A16-9214-74224BDF50D2Q47482062-7F522AD6-F5AF-4F45-AFB3-556494C54677Q47637581-B4393CF2-907F-4840-8BF3-000C342A5703Q49401353-2946CC21-0031-42C3-A43B-E90FE1E9AE54Q49959264-45AC3F5A-883A-4487-949E-8749B61CE808Q50024744-1B7F8FC8-6C86-4A23-8E48-248E01F934E6Q50036521-054A4420-C402-4639-80D8-9EAD64205B88Q52426571-5B2BEF53-3C17-4A22-A69F-365F4B7687A2Q52430423-C402E92F-CF64-4DCF-8DFE-585CE7B2B774Q52431278-59FEE76E-E15C-4AEB-A050-821D8AF1697EQ54213414-F2A3529D-CEA8-423D-8048-24A15A13DF17Q55180016-25D5C697-0360-49A8-AFC9-7D756D998B32Q55233897-588C48AD-BA8C-4C4B-B94D-CF4D1F9BAB32Q55449385-D03FDB32-C9D6-418D-A567-DD11E45C20CDQ56889817-57FA38AC-3ABD-4C00-BCF5-C24DE216B222Q56891950-402FD23C-ED00-46B1-B3E6-DD5B70BDFAE0
P2860
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
CRISPR-Cas9 mediated efficient ...... T cells from cancer patients.
@ast
CRISPR-Cas9 mediated efficient ...... T cells from cancer patients.
@en
type
label
CRISPR-Cas9 mediated efficient ...... T cells from cancer patients.
@ast
CRISPR-Cas9 mediated efficient ...... T cells from cancer patients.
@en
prefLabel
CRISPR-Cas9 mediated efficient ...... T cells from cancer patients.
@ast
CRISPR-Cas9 mediated efficient ...... T cells from cancer patients.
@en
P2093
P2860
P356
P1433
P1476
CRISPR-Cas9 mediated efficient ...... T cells from cancer patients.
@en
P2093
Baorui Liu
Fangjun Chen
Fanyan Meng
Jiankui Zhou
P2860
P2888
P356
10.1038/SREP20070
P407
P577
2016-01-28T00:00:00Z